175 related articles for article (PubMed ID: 34047191)
1. Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro.
Zev S; Raz K; Schwartz R; Tarabeh R; Gupta PK; Major DT
J Chem Inf Model; 2021 Jun; 61(6):2957-2966. PubMed ID: 34047191
[TBL] [Abstract][Full Text] [Related]
2. Compromise in Docking Power of Liganded Crystal Structures of M
Zajaček D; Dunárová A; Bucinsky L; Štekláč M
J Chem Inf Model; 2024 Mar; 64(5):1628-1643. PubMed ID: 38408033
[TBL] [Abstract][Full Text] [Related]
3. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
4. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
6. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
7. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
[TBL] [Abstract][Full Text] [Related]
8. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
9.
Tronco Pauletto PJ; Omage FB; Delgado CP; Nogara PA; Teixeira Rocha JB
Curr Drug Discov Technol; 2023; 20(2):e101022209771. PubMed ID: 36221883
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
11. Computational evaluation and benchmark study of 342 crystallographic holo-structures of SARS-CoV-2 Mpro enzyme.
Khachatryan H; Matevosyan M; Harutyunyan V; Gevorgyan S; Shavina A; Tirosyan I; Gabrielyan Y; Ayvazyan M; Bozdaganyan M; Fakhar Z; Gharaghani S; Zakaryan H
Sci Rep; 2024 Jun; 14(1):14255. PubMed ID: 38902397
[TBL] [Abstract][Full Text] [Related]
12.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
14. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
15. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
16. Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease M
Bassani D; Pavan M; Bolcato G; Sturlese M; Moro S
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215293
[TBL] [Abstract][Full Text] [Related]
17. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro.
Ngo ST; Tam NM; Pham MQ; Nguyen TH
J Chem Inf Model; 2021 May; 61(5):2302-2312. PubMed ID: 33829781
[TBL] [Abstract][Full Text] [Related]
18. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
19. Benchmarked molecular docking integrated molecular dynamics stability analysis for prediction of SARS-CoV-2 papain-like protease inhibition by olive secoiridoids.
Thangavel N; Albratty M
J King Saud Univ Sci; 2023 Jan; 35(1):102402. PubMed ID: 36338939
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the substrate-binding site of main protease for the structure-based COVID-19 drug discovery.
Firouzi R; Ashouri M; Karimi-Jafari MH
Proteins; 2022 May; 90(5):1090-1101. PubMed ID: 35119780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
